IL277934A - Cereblon ligands and bifunctional compounds comprising the same - Google Patents

Cereblon ligands and bifunctional compounds comprising the same

Info

Publication number
IL277934A
IL277934A IL277934A IL27793420A IL277934A IL 277934 A IL277934 A IL 277934A IL 277934 A IL277934 A IL 277934A IL 27793420 A IL27793420 A IL 27793420A IL 277934 A IL277934 A IL 277934A
Authority
IL
Israel
Prior art keywords
same
bifunctional compounds
cereblon
ligands
cereblon ligands
Prior art date
Application number
IL277934A
Other languages
Hebrew (he)
Original Assignee
Arvinas Operations Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/953,108 external-priority patent/US20180228907A1/en
Application filed by Arvinas Operations Inc filed Critical Arvinas Operations Inc
Publication of IL277934A publication Critical patent/IL277934A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Epoxy Compounds (AREA)
IL277934A 2018-04-13 2020-10-11 Cereblon ligands and bifunctional compounds comprising the same IL277934A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/953,108 US20180228907A1 (en) 2014-04-14 2018-04-13 Cereblon ligands and bifunctional compounds comprising the same
PCT/US2019/026570 WO2019199816A1 (en) 2018-04-13 2019-04-09 Cereblon ligands and bifunctional compounds comprising the same

Publications (1)

Publication Number Publication Date
IL277934A true IL277934A (en) 2020-11-30

Family

ID=66248825

Family Applications (3)

Application Number Title Priority Date Filing Date
IL302595A IL302595A (en) 2018-04-13 2019-04-09 Cereblon ligands and bifunctional compounds comprising the same
IL310860A IL310860A (en) 2018-04-13 2019-04-09 Cereblon ligands and bifunctional compounds comprising the same
IL277934A IL277934A (en) 2018-04-13 2020-10-11 Cereblon ligands and bifunctional compounds comprising the same

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL302595A IL302595A (en) 2018-04-13 2019-04-09 Cereblon ligands and bifunctional compounds comprising the same
IL310860A IL310860A (en) 2018-04-13 2019-04-09 Cereblon ligands and bifunctional compounds comprising the same

Country Status (9)

Country Link
EP (1) EP3774772A1 (en)
JP (2) JP2021521192A (en)
KR (1) KR20210003804A (en)
CN (1) CN112262134B (en)
AU (2) AU2019251223A1 (en)
CA (1) CA3095912A1 (en)
IL (3) IL302595A (en)
MX (2) MX2020010571A (en)
WO (1) WO2019199816A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3209295A1 (en) 2016-11-01 2018-06-07 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
JP2021519337A (en) 2018-03-26 2021-08-10 シー4 セラピューティクス, インコーポレイテッド Cereblon binder for the degradation of Ikaras
EP3781156A4 (en) 2018-04-16 2022-05-18 C4 Therapeutics, Inc. Spirocyclic compounds
CA3103185A1 (en) 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting rpn11
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
JP2022532342A (en) 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド Anti-cancer nuclear hormone receptor targeting compound
US11890346B2 (en) * 2019-06-12 2024-02-06 Northwestern University Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC protein
WO2021011913A1 (en) * 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
EP4058464A1 (en) 2019-11-13 2022-09-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN115023419A (en) 2019-11-27 2022-09-06 凯普托尔治疗学股份有限公司 Cereblon-bound piperidine-2, 6-diones and methods of use thereof
US20230099031A1 (en) * 2019-12-17 2023-03-30 Orionis Biosciences, Inc. Bifunctional agents for protein recruitment and/or degradation
WO2021175317A1 (en) * 2020-03-06 2021-09-10 正大天晴药业集团股份有限公司 Crystal of tricyclic compound acting on crbn protein and preparation method therefor
CN115380026B (en) * 2020-03-17 2023-11-07 南京明德新药研发有限公司 Protein degradation modulators and methods of use thereof
EP4121167A1 (en) * 2020-03-21 2023-01-25 Arvinas Operations, Inc. Selective modulators of mutant lrrk2 proteolysis and associated methods of use
CN113582974B (en) * 2020-04-30 2022-05-17 江西济民可信集团有限公司 Compound as protein degradation agent and preparation method and medical application thereof
CN115996719A (en) 2020-06-19 2023-04-21 C4医药公司 BRAF degradation agent
EP4180427A1 (en) * 2020-07-09 2023-05-17 Sichuan Haisco Pharmaceutical Co., Ltd. Compound capable of inhibiting and degrading androgen receptors, and pharmaceutical compositions and pharmaceutical uses thereof
CN114341128B (en) * 2020-07-24 2024-06-25 恩瑞生物医药科技(上海)有限公司 Bifunctional protein degradation targeting chimeric compound, preparation method and medical application thereof
CN114133379B (en) * 2020-09-04 2024-02-13 南京奥瑞药业有限公司 Heterocyclic compound, preparation method, intermediate, composition and application thereof
CN114262319B (en) * 2020-12-01 2023-05-05 南昌奥瑞药业有限公司 Bifunctional molecule, preparation method and application thereof
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
CN112679338A (en) * 2020-12-28 2021-04-20 丽珠集团新北江制药股份有限公司 Method for preparing oxazoline insecticide alfilana intermediate
CN112707809B (en) * 2020-12-30 2023-08-29 丽珠集团新北江制药股份有限公司 Method for preparing oxazoline insecticide fluorine Lei Lana intermediate
AU2022207648A1 (en) 2021-01-13 2023-07-27 Monte Rosa Therapeutics Ag Isoindolinone compounds
EP4289841A1 (en) * 2021-02-04 2023-12-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Benzo seven-membered ring bifunctional compound and application thereof
MX2023011241A (en) 2021-03-23 2023-10-03 Nuvation Bio Inc Anti-cancer nuclear hormone receptor-targeting compounds.
EP4317146A1 (en) * 2021-03-29 2024-02-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Tetrahydronaphthalene compound, and preparation method therefor and use thereof in medicine
CN115141179A (en) * 2021-03-31 2022-10-04 江苏恒瑞医药股份有限公司 Novel benzo heterocyclic derivatives, preparation method and application thereof in medicine
EP4334314A1 (en) 2021-05-03 2024-03-13 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CA3217417A1 (en) 2021-05-05 2022-11-10 Kevin M. Guckian Compounds for targeting degradation of bruton's tyrosine kinase
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
AU2022308734A1 (en) 2021-07-07 2024-02-22 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
WO2023283372A1 (en) 2021-07-07 2023-01-12 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
WO2023283425A1 (en) 2021-07-09 2023-01-12 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2
EP4385985A1 (en) * 2021-08-11 2024-06-19 Xizang Haisco Pharmaceutical Co., Ltd. Heterocyclic derivative, and composition and pharmaceutical use thereof
AU2022370021A1 (en) * 2021-10-22 2024-05-09 Gluetacs Therapeutics (Shanghai) Co., Ltd. Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications
CN114516810B (en) * 2022-01-18 2023-12-26 浙江奥翔药业股份有限公司 Process for preparing pharmaceutical intermediate 2-amino-4-hydroxybenzoic acid
CN114085213B (en) * 2022-01-20 2022-03-25 苏州国匡医药科技有限公司 Preparation method of ARV-471
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CN117229286A (en) * 2022-06-14 2023-12-15 海创药业股份有限公司 Aromatic compound, preparation method thereof and application thereof in preparation of estrogen receptor degradation agent
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024006781A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and use thereof
WO2024015412A1 (en) * 2022-07-12 2024-01-18 Regents Of The University Of Michigan Tetrahydronaphthalene derivatives as estrogen receptor degraders
KR20240025485A (en) * 2022-08-17 2024-02-27 한국화학연구원 Compounds for inhibiting or degrading CDK2 and/or CDK9 and medical uses thereof
CN115403561B (en) * 2022-08-22 2024-03-08 西安交通大学 Intracellular self-assembled protein degradation agent based on thalidomide analogue, and preparation method and application thereof
WO2024054955A1 (en) * 2022-09-08 2024-03-14 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and methods of treating disease
WO2024067793A1 (en) * 2022-09-29 2024-04-04 海南先声再明医药股份有限公司 Fused ring compounds and use thereof
WO2024067781A1 (en) * 2022-09-29 2024-04-04 江苏恒瑞医药股份有限公司 Pharmaceutically acceptable salt and crystal form of tetrahydronaphthalene derivative, and preparation method
CN117801051A (en) * 2022-09-30 2024-04-02 苏州德亘生物医药有限公司 Medicine for treating human tumor by eRF3a targeting protein degradation mechanism
CN116751186A (en) * 2022-12-23 2023-09-15 南京知和医药科技有限公司 Preparation and application of estrogen receptor modulator

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
PE20020354A1 (en) 2000-09-01 2002-06-12 Novartis Ag HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
CN100383139C (en) * 2005-04-07 2008-04-23 天津和美生物技术有限公司 Piperidine-2,6-dione derivatives capable of inhibiting cell from releasing tumor necrosis factor
CA2823837A1 (en) 2010-12-07 2012-06-14 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
EP2802608A4 (en) 2012-01-12 2015-08-05 Univ Yale Compounds&methods for the enhanced degradation of targeted proteins&other polypeptides by an e3 ubiquitin ligase
CN105050605A (en) 2012-06-25 2015-11-11 翁科埃蒂克斯股份公司 Method of treating lymphoma using thienotriazolodiazepine compounds
CN105164135A (en) 2013-02-22 2015-12-16 拜耳医药股份有限公司 4-substituted pyrrolo- and pyrazolo-diazepines
US20160272635A1 (en) 2013-07-23 2016-09-22 Bayer Pharma Aktiengesellschaft Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
US20150051208A1 (en) 2013-08-14 2015-02-19 Boehringer Ingelheim International Gmbh Pyridinones
US9428513B2 (en) 2013-11-07 2016-08-30 Boehringer Ingelheim International Gmbh Triazolopyrazine
MX370535B (en) 2013-11-18 2019-12-17 Forma Therapeutics Inc Tetrahydroquinoline compositions as bet bromodomain inhibitors.
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
JP6351306B2 (en) 2014-03-06 2018-07-04 キヤノン株式会社 Image processing apparatus, image processing apparatus control method, and program
KR20210132233A (en) * 2014-04-14 2021-11-03 아비나스 오퍼레이션스, 인코포레이티드 Imide-based modulators of proteolysis and associated methods of use
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2015195863A1 (en) 2014-06-20 2015-12-23 Constellation Pharmaceuticals, Inc. Hydrated 2-((4s)-6-(4-chlorophenyl)-1 -methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
BR112017006342A2 (en) 2014-10-02 2017-12-19 Glaxosmithkline Ip No 2 Ltd benzenesulfonic acid salt compound, crystalline solid state form, pharmaceutical composition, combination pharmaceutical, method of treating disease or conditions, use of a benzenesulfonic acid salt compound, and process for preparing a benzenesulfonic acid salt compound benzenesulfonic acid.
BR112017008714A2 (en) 2014-10-27 2017-12-19 Tensha Therapeutics Inc bromodomain inhibitors
JP6815318B2 (en) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド How to Induce Targeted Proteolysis by Bifunctional Molecules
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
JP6873433B2 (en) * 2015-06-04 2021-05-19 アルヴィナス・オペレーションズ・インコーポレイテッド Imid modifiers for proteolysis and related uses
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017197056A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP3455219A4 (en) * 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2018052949A1 (en) * 2016-09-13 2018-03-22 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet protein degraders
US11466028B2 (en) * 2016-09-13 2022-10-11 The Regents Of The University Of Michigan Fused 1,4-oxazepines as BET protein degraders
US10584101B2 (en) * 2016-10-11 2020-03-10 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
HRP20231537T1 (en) * 2016-12-01 2024-03-15 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
US10723717B2 (en) * 2016-12-23 2020-07-28 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
US10604506B2 (en) * 2017-01-26 2020-03-31 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US20180353501A1 (en) * 2017-06-09 2018-12-13 Arvinas, Inc. Modulators of proteolysis and associated methods of use
US20210154184A1 (en) * 2017-07-12 2021-05-27 Dana-Farber Cancer Institute, Inc. Compounds for tau protein degradation
TWI793151B (en) * 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
CN109422733A (en) * 2017-09-03 2019-03-05 上海美志医药科技有限公司 One kind inhibits and the compound for the tyrosine protein kinase ALK that degrades
WO2019148055A1 (en) * 2018-01-26 2019-08-01 Yale University Imide-based modulators of proteolysis and methods of use

Also Published As

Publication number Publication date
CN112262134A (en) 2021-01-22
JP2023175957A (en) 2023-12-12
EP3774772A1 (en) 2021-02-17
MX2023002134A (en) 2023-03-16
AU2019251223A1 (en) 2020-11-26
AU2023248067A1 (en) 2023-11-02
IL302595A (en) 2023-07-01
KR20210003804A (en) 2021-01-12
MX2020010571A (en) 2021-01-08
WO2019199816A1 (en) 2019-10-17
JP2021521192A (en) 2021-08-26
CN112262134B (en) 2024-05-24
CA3095912A1 (en) 2019-10-17
IL310860A (en) 2024-04-01

Similar Documents

Publication Publication Date Title
IL277934A (en) Cereblon ligands and bifunctional compounds comprising the same
IL268069A (en) Cereblon ligands and bifunctional compounds comprising the same
SG11202100931QA (en) Muscle-targeting complexes and uses thereof
PL3805198T3 (en) Compound, salt thereof and lipid particles
EP3826721C0 (en) Naphthyridine compounds and uses thereof
IL277502A (en) Compounds and uses thereof
IL267184A (en) Phenylamidines and the use thereof as fungicides
IL272006A (en) Bifunctional compounds
IL312725A (en) Pladienolide compounds and their use
SG11202009138QA (en) Silicon-terminated organo-metal compounds and processes for preparing the same
SG11202009175RA (en) Silicon-terminated organo-metal compounds and processes for preparing the same
GB201901651D0 (en) The geness project
IL279483A (en) Cyanotriazole compounds and uses thereof
IL280644A (en) Magnesium-serinate compound and use thereof
GB201902321D0 (en) The zeus project
SG11202002422WA (en) Novel phenylpyridine derivative and pharmaceutical composition comprising the same
IL267258A (en) Phenoxyphenylamidines and the use thereof as fungicides
GB201801102D0 (en) New compounds and uses
EP3870044A4 (en) Complexes and ligands
GB201902311D0 (en) The nautica project
GB201806349D0 (en) New compounds and uses
EP3659125C0 (en) Lock and apparatus comprising the same
EP3448780A4 (en) Packing member and cooking apparatus having the same
IL283540A (en) Dock1-inhibiting compound and use thereof
GB201808686D0 (en) The dogtooth